Search over 3,000 reports

    PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

    PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017
    Date: Dec, 2017
    Type: Pharmaceutical
    Pages: 311
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0001
    DelveInsight's, "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.

    This Report provides comprehensive insights across PD-1 and PD-L1 Inhibitors including detailed Marketed product profiles. The report has information on detailed pipeline portfolio including Phase III, Phase II, Phase I, Pre-Clinical and Discovery Products. With more than 50 products in various stages of development, the pipeline seems encouraging which has made PD-1 and PD-L1 the most talked about Immuno-oncology target.

    There are 50+products in pipeline and 5 products have been marketed so far. The focus is majorly on the antibody-based interventions targeting programmed cell death protein 1 (PD-1) on T lymphocytes and its principal ligand (PD-L1) on tumor cells to restore latent anti-tumor immunity.

    KEY COVERAGE AND BENEFITS:

    1. In-depth analysis of the 50+ pipeline assets.
    2. Pipeline landscape provides a deep dive into clinical, pre-clinical and discovery molecules.
    3. Extensive coverage of Technology implemented by companies in this space.
    4. Licensing and Deals related to PD-1 and PD-L1 inhibitors are also covered.
    5. Insights on marketed products including detailed marketed product profiles. Also includes Historical and Five years forecasted sales for Marketed products (Opdivo, Keytruda, Tecentriq, Bavencio and Imfinzi).
    6. Extensive coverage of ASCO 2017 updates and related insights.
    7. Therapeutic assessment by molecule type, route of administration, monotherapy and combination products.
    8. Detailed information on inactive projects in the pipeline for PD-1 & PD-L1 Inhibitors.
    9. Information to identify emerging players with potentially lucrative products.
    Executive Summary
    Technology
    Product Type by Specificity
    ASCO 2017 Highlights
    Programmed Death 1 (PD-1)
    Programmed Death Ligand 1 (PD-L1)
    Role of PD-1 and PD-L1 pathways
    MOA of PD-1 and PD-L1 inhibitors
    Significance of PD-1 and PD-L1 inhibitors
    PD-1 and PD-L1 Active Therapy Areas & Epidemiology
    Biomarkers - PD-1 and PD-L1 inhibitors
    Major issues with PD-L1 as a Biomarker
    Market Overview
    Comparative Analysis of Pipeline & Marketed Products
    Marketed Drug Candidate Profiles
    ASCO 2017 Updates
    Pipeline Therapeutics
    Comparative Analysis
    Late Stage Products (Phase III)
    Comparative Analysis
    Late Stage(Phase III) ProductProfiles
    Mid Stage Products (Phase II)
    Comparative Analysis
    Mid Stage(Phase II) ProductProfiles
    Early Stage Products (Phase I and IND)
    Comparative Analysis
    Early Stage(Phase I and IND) Product Profiles
    Pre-clinical and Discovery Stage Products
    Comparative Analysis
    Pre-clinical and Discovery Stage Product Profiles
    Therapeutic Assessment: Active Products
    Assessment by Monotherapy Products
    Assessment by Route of Administration
    Assessment by Stage and Route of Administration
    Assessment by Molecule Type
    Assessment by Stage and Molecule Type
    Dormant Products
    Comparative Analysis
    Appendix
    Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
    Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
    Table 3: Late Stage Products (Phase III)
    Table 4: Mid Stage Products (Phase II)
    Table 5: Early Stage Products (Phase I and IND)
    Table 6: Pre-clinical and Discovery Stage Products
    Table 7: Assessment by Monotherapy Products
    Table 8: Assessment by Combination Products
    Table 9: Assessment by Route of Administration
    Table 10: Assessment by Stage and Route of Administration
    Table 11: Assessment by Molecule Type
    Table 12: Assessment by Stage and Molecule Type
    Table 13: Dormant Products
    Figure 1: Illustration: T cell interaction with cancer
    Figure 2: Illustration: PD-L1/PD-1 Pathway
    Figure 3: Illustration: MOA of PD-1 and PD-L1
    Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
    Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
    Figure 6: Late Stage Products (Phase III)
    Figure 7: Mid Stage Products (Phase II)
    Figure 8: Early Stage Products (Phase I)
    Figure 9: Pre-clinical Stage and Discovery Products
    Figure 10: Assessment by Monotherapy Products
    Figure 11: Assessment by Route of Administration
    Figure 12: Assessment by Stage and Route of Administration
    Figure 13: Assessment by Molecule Type
    Figure 14: Assessment by Stage and Molecule Type
    Figure 15: Dormant Products
    PD-1 and PD-L1 Inhibitors Therapy Pipeline scenario

    Current Prominent Research Areas and Key Players

    Collaborations details and Deal values

    Technologies and Targeted antigens

    Pipeline product profiles CAR-T Technologies and Targeted Antigens

    Licensing opportunities

    Market Drivers and Barriers

    SWOT Analysis
    • Single User License
      (20% Off)
      $3,250.00
    • Site License
      (30% Off)
      $6,500.00
    • Global License
      (40% Off)
      $9,750.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap